Company news
Eledon Pharmaceuticals, Inc. news in 2026
Eledon Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.
Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting
October 26, 2026
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
October 5, 2026
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
September 22, 2026
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
September 9, 2026
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
September 3, 2026
Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026
Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus
June 22, 2026
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine
June 7, 2026
Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
June 4, 2026
Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress
May 20, 2026
Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
March 19, 2026
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
March 15, 2026
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
March 9, 2026
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
March 4, 2026
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 5, 2026
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium
January 23, 2026
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
January 8, 2026
Decks in 2026
- Investor Presentation (September 2026)
Investor deck · 33 slides · September 2026